Unveiling the Pharmacological Mechanism of Cosmos Caudatus Compounds as Lung Cancer Drug Candidates: Pharmacology Networking, Molecular Docking, and Experimental Validation

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Abdul Halim Umar, Citra Surya Ningsi Biringallo, Pratiwi Intan Tuyuwale, Anita Kila, Karin Dian Febyola, Reny Syahruni, Wahyu Hendrarti, Mohamad Rafi, Diah Ratnadewi
{"title":"Unveiling the Pharmacological Mechanism of Cosmos Caudatus Compounds as Lung Cancer Drug Candidates: Pharmacology Networking, Molecular Docking, and Experimental Validation","authors":"Abdul Halim Umar,&nbsp;Citra Surya Ningsi Biringallo,&nbsp;Pratiwi Intan Tuyuwale,&nbsp;Anita Kila,&nbsp;Karin Dian Febyola,&nbsp;Reny Syahruni,&nbsp;Wahyu Hendrarti,&nbsp;Mohamad Rafi,&nbsp;Diah Ratnadewi","doi":"10.1007/s12247-025-09989-0","DOIUrl":null,"url":null,"abstract":"<div><p><i>Cosmos caudatus</i> is a traditional Indonesian medicinal plant commonly used in the treatment of cancer, hypertension, diabetes, osteoporosis, and other potential health conditions. However, the mechanisms behind its compounds, targets, diseases, disease pathways, and their molecular profiles in treating lung cancer remain unclear. Therefore, a comprehensive approach is required to study these mechanisms by integrating metabolomics, bioinformatics, and in vitro experimental validation to explore the active compounds, targets, diseases, disease pathways, and molecular mechanisms involved in the treatment of lung cancer. The active compounds were identified through analysis using ultrahigh-performance liquid chromatography-quadrupole-orbital ion trap-high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS), and the screening of active compounds was conducted based on ADMET parameters. Potential compounds from <i>C. caudatus</i> and lung cancer-related targets were retrieved from public databases, such as SwissTargetPrediction, DisGeNET, DrugBank, GeneCards, PharmGKB, and TTD. Gene Ontology (GO) analysis of the targets was performed using DAVID, and protein–protein interactions (PPI) were analyzed using STRING and Cytoscape. A pharmacological network was constructed with Cytoscape. Finally, molecular docking analysis was conducted to predict and validate the interactions between <i>C. caudatus</i> compounds and core lung cancer targets. The metabolomic approach identified 66 compounds in the leaves, of which 13 met the criteria for gastrointestinal drugs. The compounds 3’,4’,5,7-tetrahydroxyflavone, AKT1 target, lung neoplasms diseases, and PIP3 activating AKT signalling pathway, became the core target with the highest degree value in the pharmacological network formed. In the protein-protein interaction (PPI) network, AKT1 again became the core target with the highest degree value. Gene Ontology (GO) functional enrichment analysis revealed that the biological processes, molecular functions, cellular components, and KEGG pathways in lung cancer were phosphorylation, cytoplasm, protein binding, and cancer pathways, respectively. The three compounds with the best binding energy and hydrogen bonding were 3’,4’,5,7-tetrahydroxyflavone-AKT1 (9C1W), gamma-mangostin-EGFR (3P0V), and cratoxyarborenone E-TNF (1XU1), with binding energies of − 10.8, − 8.9, and − 9.6 kcal/mol, respectively. The methanol extracts inhibited A549 cells at a concentration of 156.12 µg/mL. The combination of these methods provides insights into the pharmacological mechanisms of <i>C. caudatus</i> compounds in the treatment of lung cancer.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09989-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Cosmos caudatus is a traditional Indonesian medicinal plant commonly used in the treatment of cancer, hypertension, diabetes, osteoporosis, and other potential health conditions. However, the mechanisms behind its compounds, targets, diseases, disease pathways, and their molecular profiles in treating lung cancer remain unclear. Therefore, a comprehensive approach is required to study these mechanisms by integrating metabolomics, bioinformatics, and in vitro experimental validation to explore the active compounds, targets, diseases, disease pathways, and molecular mechanisms involved in the treatment of lung cancer. The active compounds were identified through analysis using ultrahigh-performance liquid chromatography-quadrupole-orbital ion trap-high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS), and the screening of active compounds was conducted based on ADMET parameters. Potential compounds from C. caudatus and lung cancer-related targets were retrieved from public databases, such as SwissTargetPrediction, DisGeNET, DrugBank, GeneCards, PharmGKB, and TTD. Gene Ontology (GO) analysis of the targets was performed using DAVID, and protein–protein interactions (PPI) were analyzed using STRING and Cytoscape. A pharmacological network was constructed with Cytoscape. Finally, molecular docking analysis was conducted to predict and validate the interactions between C. caudatus compounds and core lung cancer targets. The metabolomic approach identified 66 compounds in the leaves, of which 13 met the criteria for gastrointestinal drugs. The compounds 3’,4’,5,7-tetrahydroxyflavone, AKT1 target, lung neoplasms diseases, and PIP3 activating AKT signalling pathway, became the core target with the highest degree value in the pharmacological network formed. In the protein-protein interaction (PPI) network, AKT1 again became the core target with the highest degree value. Gene Ontology (GO) functional enrichment analysis revealed that the biological processes, molecular functions, cellular components, and KEGG pathways in lung cancer were phosphorylation, cytoplasm, protein binding, and cancer pathways, respectively. The three compounds with the best binding energy and hydrogen bonding were 3’,4’,5,7-tetrahydroxyflavone-AKT1 (9C1W), gamma-mangostin-EGFR (3P0V), and cratoxyarborenone E-TNF (1XU1), with binding energies of − 10.8, − 8.9, and − 9.6 kcal/mol, respectively. The methanol extracts inhibited A549 cells at a concentration of 156.12 µg/mL. The combination of these methods provides insights into the pharmacological mechanisms of C. caudatus compounds in the treatment of lung cancer.

揭示宇宙尾状化合物作为肺癌候选药物的药理机制:药理学网络、分子对接和实验验证
尾藤是一种传统的印尼药用植物,通常用于治疗癌症、高血压、糖尿病、骨质疏松症和其他潜在的健康问题。然而,其化合物、靶点、疾病、疾病途径及其治疗肺癌的分子谱背后的机制尚不清楚。因此,需要综合代谢组学、生物信息学、体外实验验证等方法对这些机制进行研究,探索参与肺癌治疗的活性化合物、靶点、疾病、疾病通路和分子机制。采用超高效液相色谱-四极轨道离子阱-高分辨率质谱(UHPLC-Q-Orbitrap HRMS)对活性化合物进行鉴定,并基于ADMET参数对活性化合物进行筛选。从SwissTargetPrediction、DisGeNET、DrugBank、GeneCards、PharmGKB和TTD等公共数据库中检索尾状梭菌和肺癌相关靶点的潜在化合物。使用DAVID对靶点进行基因本体(GO)分析,使用STRING和Cytoscape分析蛋白-蛋白相互作用(PPI)。利用Cytoscape构建药理学网络。最后,进行分子对接分析,预测并验证尾状梭菌化合物与核心肺癌靶点之间的相互作用。代谢组学方法鉴定了66种化合物,其中13种符合胃肠道药物标准。化合物3′,4′,5,7-四羟黄酮,AKT1靶点,肺肿瘤疾病,PIP3激活AKT信号通路,成为形成的药理学网络中度值最高的核心靶点。在蛋白-蛋白相互作用(PPI)网络中,AKT1再次成为度值最高的核心靶点。基因本体(Gene Ontology, GO)功能富集分析表明,肺癌的生物学过程、分子功能、细胞组分和KEGG通路分别为磷酸化、细胞质、蛋白结合和肿瘤通路。3′,4′,5,7-四羟黄酮- akt1 (9C1W)、γ -山竹素- egfr (3P0V)和甲氧基甲素酮E-TNF (1XU1)的结合能和氢键最好,其结合能分别为- 10.8、- 8.9和- 9.6 kcal/mol。甲醇提取物对A549细胞的抑制作用浓度为156.12µg/mL。这些方法的结合提供了对尾藤化合物治疗肺癌的药理机制的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信